Main Article Content

Authors

Introduction: Secondary hypertension corresponds to 15 % of the causes of arterial hypertension, and among them, primary hyperaldosteronism presents a variable incidence of about 3% in hypertensive patients. It has a slightly higher prevalence in women, between 30 and 60 years, and is usually unilateral. Case presentation: The authors describe the clinical case of a patient, followed by severe hypertension medicated with four antihypertensive drugs for tension stabilization, maintaining systolic arterial tensions superior to 170 mmHg. In the aetiological study of hypertension, analytical alterations suggested hyperaldosteronism and a nodular lesion was detected in the left adrenal gland. The patient was submitted to surgery and excision of the lesion was done with histological confirmation of the diagnosis of corticomedullary adenoma of the adrenal gland. The patient presented improvement of the tension profile, with the need to suspend two of the four antihypertensive drugs and to reduce the dose of the remaining ones. Conclusion: A tumor of the adrenal cortex producing aldosterone is the main cause of primary hyperaldosteronism and should always be excluded when the presence of di cult to control, severe hypertension is detected, since the standard treatment is surgical, leading to a stabilization of the tension pattern after a few months.
Cascais Costa, J., Rua, J. R., Silva, A., & Rodrigues, A. (2018). Resistant Hypertension: A Clinical Case. Revista Ciencias De La Salud, 16(3), 567–572. https://doi.org/10.12804/revistas.urosario.edu.co/revsalud/a.7272

Aronova A, III TJF, Zarnegar R. Management of hypertension in primary aldosteronism. World J Cardiol. 2014;6(5):227-33. doi: 10.4330/wjc.v6.i5.227.

Catena C, Colussi GL, Brosolo G, Bertin N, Novello M, Palombe A, et al. Salt, aldosterone, and parathyroid hormone: What is the relevance for organ damage? Int J Endocrinol. 2017;2017:4397028. doi: 10.1155/2017/4397028.

Prkacin I, Balenovic D, Djermanovic-Dobrota V, Lukac I, Drazic P, Pranjic I-K. Resistant hypertension and chronotherapy. Mater Sociomed. 2015;27(2):118-21. doi: 10.5455/ msm.2015.27.118-121.

Koch CA, Chrousos GP. Overview of endocrine hypertension. In: De Groot LJ, Chrousos G, Dungan K, et al., editors. Endotext [internet]. South Dartmouth (MA): MDText.com, Inc.; 2000 [cited 2016 Oct 26]. Available from: https://www.ncbi.nlm.nih.gov/books/ NBK278980/

Kumar N, Calhoun DA, Dudenbostel T. Management of patients with resistant hypertension: current treatment options. Integr Blood Press Control. 2013;6:139-151. doi:10.2147/ IBPC.S33984.

Vaidya A, Dluhy R. Hyperaldosteronism. In: De Groot LJ, Chrousos G, Dungan K, et al., editors. Endotext [internet]. South Dartmouth (MA): MDText.com, Inc.; 2000 [cited 2016 Oct 19]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279065/

Park JJ, Park BK, Kim CK. Adrenal imaging for adenoma characterization: imaging features, diagnostic accuracies and differential diagnoses. The British Journal of Radiology. 2016;89(1062):20151018. doi: 10.1259/bjr.20151018.

Díaz J, Zúñiga E. Síndrome de Conn: descripción de un caso clínico. Hipertensión (Madr.). 2007;24(4):181-4.

Kim SH, Ahn JH, Hong HC, Choi HY, Kim YJ, Kim NH, et al. Changes in the clinical manifestations of primary aldosteronism. The Korean Journal of Internal Medicine. 2014;29(2):217-225. doi: 10.3904/kjim.2014.29.2.217.

Uresti-Flores E, Saucedo-Trevinõ L, Gámez-Barrera H, Melo-Gastón M, Valdés-Cruz E, García-de Léon L. Síndrome de Conn. Med Int Méx 2015;31:210-16.

Downloads

Download data is not yet available.

Most read articles by the same author(s)